Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment

Journal of Infectious Diseases

Volumn 183, Issue 5, 2001, Pages 730-735

  David, Denis ^a   Naït Ighil, Lella ^b   Dupont, Bertrand ^b   Maral, Jean ^c   Gachot, Bertrand ^b   Thèze, Jacques ^a  

^a INSTITUT PASTEUR   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Chiron Biopharmaceuticals Europe   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INTERLEUKIN 2; PROTEIN BCL 2; RECOMBINANT INTERLEUKIN 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOTHERAPY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; PILOT STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIGENS, CD45; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; PILOT PROJECTS; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; VIRAL LOAD;

EID: 0035282639     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/318824     Document Type: Article

References (39)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Immune restoration with antiretroviral therapies
4. HIV treatment failure: Testing for HIV resistance in clinical practice
5. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
6. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy
7. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy
8. Interleukin-2: Inception, impact and implications
9. Interleukin-2 and its receptors: Recent advances and new immunological functions
10. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study
11. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial
12. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
13. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons
14. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients
15. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/mL CD4 T cells and undetectable plasma virus load
16. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection
17. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection
18. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
19. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy
20. Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets
21. Diminished spontaneous apoptosis in lymphocytes from human immunodeficiency virus-infected long-term nonprogressors
22. 2 microglobulin concentration and disease evolution
23. Mechanisms of HIV-associated lymphocyte apoptosis
24. In vivo analysis of Fas/FasL interactions in HIV-infected patients
25. Down-regulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin-2
26. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy
27. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis
28. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
29. Plasma cytomegalovirus DNA, pp65 antigenemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy
30. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy
31. Turnover of naive- and memory-phenotype T cells
32. + T-cell regeneration HIV-infected adults
33. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection
34. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy
35. Effect of recent thymic emigrants on progression of HIV-1 disease
36. Factors influencing T-cell turnover in HIV-1 seropositive patients
37. Identification of a human recent thymic emigrant phenotype
38. Cellular environments and apoptosis: Tissue microenvironments control activated T-cell death
39. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection: Correlation with its ability to block culture-induced down-modulation of Bcl-2